USA. Rezenopy, the 10 Mg Naloxone Nasal Spray, Enters the OD Antidote Market
USA. Rezenopy, the 10 Mg Naloxone Nasal Spray, Enters the OD Antidote Market
Two years after its approval by the Food and Drug Administration, opioid-overdose reversal product Rezenopy is about to make its commercial launch. At 10 mg of naloxone per nasal spray, each dose of Rezenopy is the equivalent of two-and-a-half doses of Narcan. It’s the highest-dose naloxone nasal spray available—a distinction that comes with no proven benefits to people at risk of overdose, but does help the product serve its higher purpose of being moderately attractive to shareholders. Filter, USA, 23.03.2026)
- Erstellt am .